Project Details
| Short title | eVOLVE-Lung02 |
|---|---|
| Status | Not started |
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)
- Arulananda, Surein (Primary Chief Investigator (PCI))
Project: Research